Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 5/20 | 0.48 |
| ▸ | FGF2 | P09038 | 2/20 | 0.48 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 11/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | BDNF | P23560 | 2/20 | 0.31 |
| ▸ | PTN | P21246 | 1/20 | 0.31 |
| ▸ | MDK | P21741 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789358 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL12798095 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL16329943 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL14368581 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL1786656 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL14368576 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL14368288 | 1.00 | FGF1 (0.48) | FGF1FGF2SERPINC1HPSEF10 | |
| SCHEMBL1786663 | 0.96 | FGF1 (0.45) | FGF1FGF2SERPINC1HPSEBDNF | |
| SCHEMBL12798102 | 0.96 | FGF1 (0.45) | FGF1FGF2SERPINC1HPSEBDNF | |
| SCHEMBL16317603 | 0.93 | FGF1 (0.50) | FGF1FGF2SERPINC1HPSEBDNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987216-B2 | Polysulfated glycosides and salts thereof | Teva Hungary Pharmaceutical Marketing Private Limited Company (HU) | 2015-03-24 | — | — | US | claimed |
| US-20110118198-A1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2011-05-19 | — | — | US | claimed |
| US-7902158-B2 | Polysulfated glycosides and salts thereof | Ivax Drug Research Ltd. (HU) | 2011-03-08 | — | — | US | claimed |
| EP-1778709-B1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RES INST LTD (HU) | 2008-05-28 | — | — | EP | claimed |
| US-20070281893-A1 | Polysulfated Glycosides And Salts Thereof | IVAX DRUG RESEARCH INSTITUTE LTD (HU) | 2007-12-06 | — | — | US | claimed |
| EP-1778709-A2 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX Drug Research Institute Ltd (HU) | 2007-05-02 | — | — | EP | claimed |
| WO-2006017726-A2 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RESEARCH INSTITUTE LTD (HU) | 2006-02-16 | — | — | WO | claimed |
| US-8987216-B2 | Polysulfated glycosides and salts thereof | Teva Hungary Pharmaceutical Marketing Private Limited Company (HU) | 2015-03-24 | — | — | US | disclosed |
| US-20110118198-A1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2011-05-19 | — | — | US | disclosed |
| US-7902158-B2 | Polysulfated glycosides and salts thereof | Ivax Drug Research Ltd. (HU) | 2011-03-08 | — | — | US | disclosed |
| EP-1778709-B1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RES INST LTD (HU) | 2008-05-28 | — | — | EP | disclosed |
| US-20070281893-A1 | Polysulfated Glycosides And Salts Thereof | IVAX DRUG RESEARCH INSTITUTE LTD (HU) | 2007-12-06 | — | — | US | disclosed |
| EP-1778709-A2 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX Drug Research Institute Ltd (HU) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006017726-A2 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RESEARCH INSTITUTE LTD (HU) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118198-A1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | CFTR, AREG, STS | FGF1 1447/4885FGF2 919/4885SERPINC1 222/4885 |
| US-20070281893-A1 | Polysulfated Glycosides And Salts Thereof | CFTR, AREG, STS | FGF1 1447/4885FGF2 919/4885SERPINC1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.